DEA Archives

Dave HodesAugust 4, 2022

The pressure is ramping up on the U.S. Drug Enforcement Administration (DEA) as more lawyers, clinicians, researchers, investors and business owners working in the psychedelics industry are demanding clear answers about how the DEA should be evolving on its drug scheduling and enforcement strategy. Right now, LSD, psilocybin, MDMA and peyote (mescaline) are all listed […]

Debra BorchardtMay 18, 2022

Bright Green (NASDAQ: BGXX) is a cannabis company with no revenue that just began trading on the NASDAQ, despite the exchange’s insistence that it won’t list U.S. cannabis companies due to the product being federally illegal. Bright Green plans to produce cannabis for research purposes with the Drug Enforcement Agency‘s (DEA) blessing, which seems to […]

Dave HodesApril 18, 2022

A group of defendants recently took on the federal government to protect their rights of using the psychedelic ayahuasca in their religious ceremonies. But things didn’t go their way. The case involved the seizure of ayahuasca and the arrest of members of the North American Association of Visionary Churches (NAAVC), a California non-profit interdenominational association […]

Dave HodesMarch 4, 2022

When you see various agencies of the U.S. government getting involved in psychedelics, or changing their stance even a little (such as the DEA), that signals that the industry has hit its stride. Avenues of development open up, investor confidence increases, and researchers sense the ability to achieve goals that not only science but government […]

StaffSeptember 2, 2020

Editors note: This is a guest post by Robbert Dean. In the middle of August, the US Drug Enforcement Administration (DEA) issued an interim rule which is a treat to the cannabinoid hemp market and could impact hemp pricing. Operators in this space including farmers, traders, and extractors are now racing to determine how this […]

StaffMarch 24, 2020

Late last week, the Drug Enforcement Administration (DEA) and the Department of Justice announced action to further expand opportunities for scientific and medical research on marijuana in the United States. The Notice of Proposed Rulemaking was filed for public inspection on March 20. The proposed rule was then published in the Federal Register on Monday, March […]

Debra BorchardtSeptember 27, 2018

The Acting Administrator of the Drug Enforcement Administration has placed FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols (THC) in schedule V. GW Pharmaceutical’s (GWPH) Epidiolex had been a schedule I controlled substance, with this new directive Epidiolex (and any generic versions of the same formulation that might be […]

Debra BorchardtSeptember 20, 2018

Tilray Inc. (TLRY) has been somewhat a source of pride in the cannabis community, listing on the NASDAQ (NDAQ) with a successful Initial Public Offering (IPO). It’s a well-run respectable company with strong sales and an enviable portfolio of brands. Two things have happened this week with Tilray. The stock went on a ridiculously crazy ride […]

Video StaffMay 4, 2018

May the fourth be with you! The DEA won the case regarding Cannabidiol or CBD from the Hemp Industries Association. The Ninth Circuit appeals court ruled in favor of the DEA that wants to classify CBD as a schedule 1 controlled substance. The DEA has long believed that CBD is a marijuana extract and since […]

Debra BorchardtMay 3, 2018

It’s time for your Daily Hit of cannabis news for May 3 2018: On The Site: DEA Wins One A panel of judges for the 9th U.S. Circuit Court of Appeals rejected a challenge filed by cannabidiol (CBD) producers against a Drug Enforcement Agency rule that classifies CBD as a Schedule I drug. The rule originated in […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: DEA

DEA’s Psychedelics ‘To Do’ List Is Growing

NASDAQ Allows DEA Approved Cannabis Company To Trade

The DEA v. Religion v. Psychedelics

Feds Are Elevating Their Psychedelic Agendas

Could the DEA Be A Threat to CBD?

DEA Seeks To Expand Marijuana Research Opportunities

DEA Classifies GW Pharmaceutical’s Epidiolex As A Schedule 5 Drug

Tilray Sparks Debate In Cannabis Community

Marijuana Money May 4, 2018

The Daily Hit: May 3, 2018

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox